Furthermore, Smithen DA et al. demonstrated that the use of the 2-aminomethylene-5-sulfonylimidazole LOXL2 inhibitor significantly reduces the growth of breast cancer tumours in mouse models, resulting in strong antitumour effects 64. Here, LOXL2 is linked to breast carcinoma.